SEE Nr. 19-COP-0031-“HE-RO-IS strategic cooperation in hematology”

• Tipărire

Detalii

Accesări: 6868

.                     

Project title: “HE-RO-IS strategic cooperation in hematology”

Acronym: HERO

Beneficiary: “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca

Contract no.: F SEE Nr. 19-COP-0031

Implementation: 01.09.2020 - 30.11.2021

Project budget (lei): 696.518

Project director: Lecturer Ciprian Ionuț Tomuleasa, M.D., Ph.D

Partners:

1. IOCN Cluj, "Ion Chiricuță Oncology Institute" Cluj-Napoca
2. IRGH Cluj, "Prof. dr. Octavian Fodor" Regional Institute for Gastroenterology and Hepatology
3. Fundeni Clinical Institute, Bucharest
4. Reykjavik University Iceland

Project objectives:

Objective 1: Developing a common curriculum in hematology

• Three online conferences for the development of the common curricula in hematology O1
• One on-site conference at Reykjavik University for the development of the common curricula in hematology O1

Results

Hemophilia Curricula RO-IS

• Hemophilia curricula
• Acquired hemophilia
• Clinical cases
• Genetics of hemophilia
• Hemophilia management in adolescents
• Hemophilia management in the aging patient
• Joint physical examination
• Pharmacokinetics of hemophilia drugs
• Physiotherapy of the hemophilia joints
• Prophylaxis

Objective 2: Setting up a hemophilia e-platform at transnational level

Results

• Hemophilia e-platform - https://rrph.wpengine.com 

Objective 3: Developing and submitting 5 joint articles to peer review publications

Results: 10 joint articles

• Zimta AA, Sigurjonsson OE, Gulei D, Tomuleasa C. The Malignant Role of Exosomes as Nanocarriers of Rare RNA Species. Int J Mol Sci. 2020 Aug 15;21(16):5866.

• Catalin Constantinescu, Sergiu Pasca, Alina-Andreea Zimta , Tiberiu Tat , Ioana Rus , Patric Teodorescu , Sabina Iluta , Alina Tanase , Anca Colita , Olafur Sigurjonsson , Hermann Einsele , Ciprian Tomuleasa Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies. J Clin Med. 2020 Sep 8;9(9):2903.

• Minodora Desmirean , Sebastian Rauch , Ancuta Jurj , Sergiu Pasca , Sabina Iluta , Patric Teodorescu , Cristian Berce , Alina-Andreea Zimta , Cristina Turcas , Adrian-Bogdan Tigu , Cristian Moldovan , Irene Paris , Jakob Steinheber , Cedric Richlitzki , Catalin Constantinescu , Olafur Eysteinn Sigurjonsson , Delia Dima , Bobe Petrushev, Ciprian Tomuleasa . B Cells versus T Cells in the Tumor Microenvironment of Malignant Lymphomas. Are the Lymphocytes Playing the Roles of Muhammad Ali versus George Foreman in Zaire 1974? J Clin Med. 2020 Oct 24;9(11):3412.

• Valentina Sas , Sergiu Pasca , Ancuta Jurj , Laura Pop , Hideki Muramatsu , Hiroko Ono , Delia Dima , Patric Teodorescu , Sabina Iluta , Cristina Turcas , Anca Onaciu , Raluca Munteanu , Alina-Andreea Zimta , Cristina Blag , Gheorghe Popa , Elias Daniel Alexander von Gamm , Smaranda Arghirescu , Margit Serban , Sorin Man , Mirela Marian , Bobe Petrushev , Cristian Berce , Anca Colita, Mihnea Zdrenghea , Seiji Kojima , Diana Gulei , Yoshiyuki Takahashi , Ciprian Tomuleasa MicroRNA-155-5p Plays a Critical Role in Transient Leukemia of Down Syndrome by Targeting Tumor Necrosis Factor Receptor Superfamily Members. Cell Physiol Biochem. 2020 Oct 3;54(5):994-101.

• Sergiu Pasca , Ancuta Jurj , Ciprian Tomuleasa , Mihnea Zdrenghea TET2/IDH1/2/WT1 and NPM1 Mutations Influence the RUNX1 Expression Correlations in Acute Myeloid Leukemia. Medicina (Kaunas). 2020 Nov 24;56(12):637

• Catalin Constantinescu, Sergiu Pasca, Tiberiu Tat, Patric Teodorescu, Catalin Vlad, Sabina Iluta, Delia Dima, Dana Tomescu, Ecaterina Scarlatescu, Alina Tanase, Olafur Eysteinn Sigurjonsson, Anca Colita, Hermann Einsele, Ciprian Tomuleasa. Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies? J Immunother Cancer. 2020 May;8(1):e000742.

• Deak D, Gorcea-Andronic N, Sas V, Teodorescu P, Constantinescu C, Iluta S, Pasca S, Hotea I, Turcas C, Moisoiu V, Zimta AA, Galdean S, Steinheber J, Rus I, Rauch S, Richlitzki C, Munteanu R, Jurj A, Petrushev B, Selicean C, Marian M, Soritau O, Andries A, Roman A, Dima D, Tanase A, Sigurjonsson O, Tomuleasa C. A narrative review of central nervous system involvement in acute leukemias. Ann Transl Med. 2021 Jan;9(1):68. doi: 10.21037/atm-20-3140.

• Dirzu N, Hotea I, Jitaru C, Brinza M, Urian L, Peters MC, Gal K, Popescu L, Blag C, Marian M, Pal E, Stanescu M, Cenariu D, Tarniceriu C, Serban M, Dima D, Coriu D, Tomuleasa C. Mobile Health Technology for the Personalized Therapy of Hemophilia. Front Med (Lausanne). 2021 Aug 10;8:711973. doi: 10.3389/fmed.2021.711973. PMID: 34447770; PMCID: PMC8382969.

• Pasca S, Jurj A, Zdrenghea M, Tomuleasa C. The Potential Equivalents of TET2 Mutations. https://pubmed.ncbi.nlm.nih.gov/33805247/ 
  Cancers (Basel). 2021 Mar 24;13(7):1499. doi: 10.3390/cancers13071499. PMID: 33805247; PMCID: PMC8036366.

• Tichil I, Rosenblum S, Paul E, Cleland H. Treatment of Anaemia in Patients with Acute Burn Injury: A Study of Blood Transfusion Practices. https://pubmed.ncbi.nlm.nih.gov/33514060/ 
  J Clin Med. 2021 Jan 27;10(3):476. doi: 10.3390/jcm10030476. PMID: 33514060; PMCID: PMC7865424

C1, C2, C3, C4 and C5 short term mobility of staff and students

• C1 STMS - May 2021
• C2 STMS - September 2021
• C3 STTE - May 2021
• C4 STTE - September 2021
• C5 STTE - October 2021

Translational Project Meeting 1 - TPM1

• TPM 1 - May 2021

M 1.2 MULTIPLIER EVENTS

M 1.1 - First multiplier event hosted by Fundeni Clinical Institute - 27.08.2021

M 1.2 - Second multiplier event hosted by UMPhIH - Insights in Hematology 17.09.2021

• Dr. Tomuleasa HERO presentation September 2021
• Prof. Olafur Sigurjonsson HERO presentation September 2021

 SOCIAL MEDIA DISSEMINATION

• CSID interview - Lecturer CIPRIAN TOMULEASA M.D. , Ph.D.
• DiGiTV interview - Lecturer CIPRIAN TOMULEASA M.D. , Ph.D.

Disclaimer: This website was realised with the EEA Financial Mechanism 2014-2021 financial support. Its content (text, photos, videos) does not reflect the official opinion of the Programme Operator, the National Contact Point and the Financial Mechanism Office. Responsibility for the information and views expressed therein lies entirely with the authors.